FDA Advisory Committee does not recommend that sotagliflozin receive approval for glucose lowering in adults with type 1 diabetes (T1D) and Chronic Kidney Disease (CKD)
There is a deep unmet need for therapies in addition to insulin for glucose control in people with T1D. This…
Navigating the school year with type 1 diabetes: A call to support and action
A T1D dad and physician's POV about the start of a new school year.
ADA Takeaways: Day 2
At the ADA Scientific Sessions, scientists will present the latest T1D research, all with the goal of improving lives for…
Breakthrough T1D T1D Fund Invests in vTv Therapeutics
With an investment from the Breakthrough T1D T1D Fund, vTv Therapeutics will run a phase III clinical trial of cadisegliatin…
Life with T1D: 19 Things I’ve Learned in 19+ Years
A guest post from Breakthrough T1D's social media manager, Grace Bennett, about life-with-T1D lessons she's learned in 19+ years.
Top Type 1 Diabetes Advances of Fiscal Year 2023
Breakthrough T1D highlights the top type 1 diabetes advances we've seen during fiscal year 2023, including cures and life-improving therapies.
Dexcom G7 Continuous Glucose Monitor Cleared by the FDA
Dexcom G7® Continuous Glucose Monitor system was cleared by the FDA, giving people with diabetes more options for managing their…
The Innovative Insulin Your Kids Can’t Use…Yet
What if it was safe and effective to take a rapid-acting inhaled insulin in children/teens as they start eating? The…
Glucagon: Your Friend in Low Places
Glucagon. It’s a word familiar to people with T1D, yet one most hope to avoid discussing. But what is glucagon…
